divarasib + pembrolizumab

**Divarasib + pembrolizumab** is a combination of two investigational and approved agents under clinical evaluation for the first-line treatment of adults with **KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)**. **Divarasib** is a potent, oral, small molecule **KRAS G12C inhibitor** that binds irreversibly to the cysteine 12 residue of the mutant KRAS protein, blocking its activity and oncogenic signaling. **Pembrolizumab** is a humanized monoclonal antibody targeting **programmed cell death protein 1 (PD-1)** on T cells, enhancing anti-tumor immune response by blocking the interaction with its ligands (PD-L1/PD-L2). The combination is hypothesized to provide synergistic anti-tumor effects by inhibiting oncogenic signaling and overcoming tumor immune evasion. The regimen is being developed by **Roche/Genentech** and **Merck (for pembrolizumab)** as part of ongoing phase Ib/II and phase II/III trials in NSCLC[1][2][3][5].

Other names

MK-3475MK3475MK 3475divarasib plus pembrolizumab